Our Expert Network

1. Repeating Sanofi's Ballroom Design On Two Continents 5/15/2026

   Moveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.

2. Validation Of A RIG-I–Based Functional Assay For Quantitative Detection Of Double-Stranded RNA Impurities In mRNA Drug Substance 5/13/2026

   A validated RIG-I assay adds a biology-informed layer to dsRNA testing by quantifying immunogenic impurities in IVT-derived mRNA therapeutics for deeper functional insight.

3. Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease 5/8/2026

   Suppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.

4. Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset 5/4/2026

   In this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.

5. Engineering Repeat-Dose RNA: Engineering Around Immune Recognition In Repeat-Dose RNA Therapeutics 4/30/2026

   Designing repeat-dose RNA means engineering around immune recognition — optimizing payloads, purity, and delivery early to sustain efficacy, tolerability, and durability across multiple administrations.

6. Bridging The Manufacturing Chemistries Between Drug Research And Development For Morpholino Oligos 4/29/2026

   Standardizing Morpholino chemistry could streamline development and FDA pathways, improving consistency, scalability, and delivery performance across antisense therapeutics.

7. From Supporting Component to Strategic Driver: The Evolving Role of gRNA in CRISPR Therapeutics 4/21/2026

   Guide RNA is evolving from a simple targeting reagent into a complex, engineered molecule shaped by expanding CRISPR modalities, increasing length and modification demands, and tighter integration with manufacturability, analytical control, and regulatory expectations.

8. A Novel Co-Tethered Transcription Platform For High-Yield, High-Purity mRNA Synthesis 4/15/2026

   Co-tethered transcription boosts mRNA yield and purity by organizing transcription machinery, reducing dsRNA impurities, and streamlining production for scalable RNA therapeutics.

9. A New Approach To RNA Synthesis And Purification: Rethinking A Persistent Bottleneck 4/14/2026

   Photocleavable supports enable light-triggered RNA release, reducing reliance on chromatography and streamlining synthesis, scalability, and purity for complex RNA therapeutics.

10. Oligos, mRNA, Or Gene Editing: Where Should You Bet? 4/13/2026

    Investing in RNA and gene editing requires balancing risk, timing, and scale — understanding how oligos, mRNA, and CRISPR each drive value across a converging biotech landscape.